Health and wellness company, Satipharm, has announced plans to research the effects of CBD on symptoms of perimenopause and menopause. The new clinical research follows the success of Satipharm’s phase II clinical trial which demonstrated the efficacy of the company’s CBD capsules in treating seizures associated with childhood epilepsy.
Satipharm’s phase II clinical trial successfully showed that CBD can reduce the occurrence of seizures – of an average of 73%. The company has now turned its attention to possible treatments of symptoms associated with perimenopause and menopause.
What is Perimenopause and Menopause?
Perimenopause is the period of time prior to menopause. During this time, the ovaries gradually begin to produce less estrogen, leading to some hormonal changes. Following this phase, the ovaries will eventually cease producing eggs – this is called menopause.
The research will aim to demonstrate that CBD can have a significant impact on symptoms associated with these physiological changes. Perimenopause and menopause affect women aged, on average, between 42 and 52.
Many women experience a number of unpleasant symptoms such as hot flushes; irregular menstrual cycles; night sweats; fatigue; trouble sleeping; and mood swings.
How Could CBD Benefit Menopause?
Researchers believe that cannabidiol (CBD) could have the potential to relieve a multitude of symptoms associated with perimenopause and menopause. The Cannabis derivative may have the ability to impact some relevant bodily functions, through its interaction with our endocannabinoid system (ECS).
The Endocannabinoid System is distributed throughout our bodies, in the form of receptors (CB1 and CB2) and endocannabinoids which interact with them. Cannabinoids found in the Cannabis plant, such as CBD and THC, also have the ability to interact with these receptors.
Existing research indicates that the ECS plays an essential part in bodily functions and other health aspects. For example, mood regulation; immune functions; pain; sleep; memory; fertility and reproduction; and temperature regulation.
Through the ECS, CBD may have the potential to aid in the regulation of these functions – some of which may be relevant to some symptoms of perimenopause and menopause.
Satipharm’s Clinical Trial
Satipharm is hoping to gather information from a number of women who are experiencing perimenopause and menopause. These women may already be using CBD to aid symptoms. The company is offering a discount to women who take part in the first stage of their research.
Feedback received from this research will then be used to design an appropriate Phase 2 clinical trial in which the findings can be assessed in more detail. For more information, visit Satipharm’s website.
